ReachRxResearch
Home
Research
Sign Up
Neutrophil‐Driven Inflammation in Pediatric Chronic Recurrent Multifocal Osteomyelitis
Back to Research Hub
  1. Home
  2. Research Hub
  3. Neutrophil‐Driven Inflammation in Pediat…

Neutrophil‐Driven Inflammation in Pediatric Chronic Recurrent Multifocal Osteomyelitis

Arthritis & Rheumatology·September 29Open Access
RheumatologyConfirms priorChronic Recurrent Multifocal OsteomyelitisCross-Sectional StudyBisphosphonateNSAIDTNF InhibitorPediatricZoledronate

Summary

View source

What was studied

This study investigated the role of neutrophils and the adaptor protein PSTPIP2 in human pediatric CRMO, comparing 34 CRMO patients (across untreated, NSAID, zoledronate, and anti-TNF treatment groups) to 20 healthy controls using flow cytometry, biochemical assays, and neutrophil transcriptomic profiling.

Key findings

CRMO neutrophils showed chronic activation (reduced CD62L, p=0.0016) correlating with MRI lesion burden, and PSTPIP2 protein was consistently decreased (p=0.0006) despite elevated mRNA (p=0.0005), suggesting post-transcriptional regulation; both abnormalities normalized with anti-TNF therapy.

Study limitations

Transcriptomic profiling was limited to only 4 patients and 3 controls, reducing statistical power for pathway-level findings. The cross-sectional design limits causal inference. The study does not clarify the exact post-transcriptional mechanism driving PSTPIP2 protein loss.

Clinical implications

Neutrophil activation markers (e.g., CD62L) and chemokines (CCL4, CCL4L2) may serve as disease activity biomarkers in pediatric CRMO. Anti-TNF therapy appears to reverse both neutrophil dysregulation and PSTPIP2 deficiency, providing a mechanistic rationale for its use in refractory cases.

Caveats

  • Specific anti-TNF agents used are not named in the abstract, limiting direct applicability to individual drugs
  • The study population is cross-sectional and treatment groups were not randomized, introducing potential confounding between disease severity and treatment type
  • Transcriptomic profiling was performed on a very small subset (4 patients, 3 controls), so pathway-enrichment findings should be considered exploratory and hypothesis-generating only

Related Questions

Explore related topics

What is the evidence for anti-TNF therapy in pediatric chronic recurrent multifocal osteomyelitis?How is PSTPIP2 involved in autoinflammatory bone disease?What biomarkers can help monitor disease activity in CRMO?

Publication Details

Year
2026
Journal
Arthritis & Rheumatology
Sample Size
n=54
Source
View article
Keep scrolling
More content below.
Up Next